Go to Page # Page of 47

New Developments in Myeloma and Lymphoma

 Steve Schey
Description: Study includes Diagnostics and Prognostics: Individualizing Treatment, Novel agents: New drugs, drug combinations, drug scheduling, and the role in stem cell transplantation, Immunomodulation and antibodies, resistance. Other topics discussed include individualizing treatment in the ERA, gene expression and profiling and increasing options for newly diagnosed. Potential biological targets for novel anti-myeloma drugs, and new agents in myeloma.
Views: 3395
Domain: Medical
Category: Biology
Latest developments in haematological oncology g gy
Steve Schey
Consultant Haematologist King's College Hospital NHS Foundation Trust Kings College, London g g

New developments in Myeloma and p y Lymphoma
Diagnostics and Prognostics: Diagnostics and Prognostics:
Individualising Treatment

Novel Agents: N lA t
New drugs Drug Combinations Drug Scheduling Role in Stem cell transplantation

Immunom ... See more

Recent Presentations

FDA Approach to the Opioids Crisis

Opioid Crisis is not one crisis, but multiple challenges to prescribers, patients & healthcare system. FDA is working in a prioritized way in multiple areas to confront opioid over

18 April, 2019
Ralph F. Hall
17 April, 2019

Investment Trends in Healthcare

Macroeconomic drivers are leading to an unprecedented healthcare industry change. Healthcare is one of the most impacted industry by technology breakthrough.

Danilo Mazzara
16 April, 2019